Supplemental Figure 1 from Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma
Year: 2023
Type: supplementary-materials
Abstract: S1: Ovalbumin-expressing MOC1 tumor cells (T = target) were allowed to grow in 96-well plates in the presence or absence of cisplatin for 24 hours prior to adding antigen-specific OT-1 T cells (E = effector). Impedance measurements were taken over time to determine tumor cell viability. In B and C, Impedance lines are graphed as averages of 3 replicates that have been normalized to a cell index of 1.0 at 24 hours when CTLs were added. CTLs were pretreated separately with the indicated doses of cisplatin starting at time point 0 hours, then added to the wells with MOC1 ova cells and co-treated with cisplatin throughout the rest of the experiment. Graphs are representative of two independent experiments done in triplicate.
Authors: Linda Tran, Clint T. Allen, Roy Xiao, Ellen Moore, Ruth Davis, So-Jin Park, Katie Spielbauer, Carter Van Waes, Nicole C. Schmitt
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362628867